Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review-Reference-Cited by-同舟云学术

Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review

Published:2022-10-25 Issue:2 Volume:64 Page:273-282
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Shahzad Moazzam¹²^ORCID,Chaudhary Sibgha Gull¹,Tariq Ezza¹³,Mushtaq Ali Hassan¹,Anwar Iqra¹,Ahmed Nausheen¹,Bansal Rajat¹,Lutfi Forat¹,Balusu Ramesh¹,Abdelhakim Haitham¹,Yacoub Abdulraheem¹^ORCID,Hematti Peiman⁴,Singh Anurag K.¹,McGuirk Joseph P.¹,Mushtaq Muhammad Umair¹^ORCID

Affiliation:

1. Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA

2. Moffitt Cancer Center, University of South Florida, Tampa, FL, USA

3. University of Toledo Medical Center, Toledo, OH, USA

4. University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2136947

Reference45 articles.

1. Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives

2. Cancer statistics, 2022

3. Cancer statistics, 2020

4. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

5. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What clinicians should know about surrogate end points in hematologic malignancies;Blood;2024-07-04